ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon PrintIcon Twitter

Samsung Biologics snags $1.5bn in orders on pandemic rush

South Korean drug-making powerhouse sees stock price double this year

Samsung Biologics plans to build its fourth plant in the South Korean city of Incheon to handle a rush of orders amid the coronavirus pandemic. (Photo courtesy of Samsung Biologics)

SEOUL -- Samsung Biologics closed $1.5 billion worth of orders in the past three months, as the world's leading contract biopharmaceutical manufacturer topped its sales for all of 2019 by 150% due to the coronavirus pandemic.

Sponsored Content

About Sponsored Content This content was commissioned by Nikkei's Global Business Bureau.

Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.

Celebrate our next chapter
Free access for everyone - Sep. 30

Find out more